Current issues regarding treatment of mitochondrial fatty acid oxidation disorders
- 10 September 2010
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (5) , 555-561
Abstract
Treatment recommendations in mitochondrial fatty acid oxidation (FAO) defects are diverse. With implementation of newborn screening and identification of asymptomatic patients, it is necessary to define whom to treat and how strictly. We here discuss critical questions that are currently under debate. For some asymptomatic long‐chain defects, long‐chain fat restriction plays a minor role, and a normal diet may be introduced. For patients presenting only with myopathic symptoms, e.g., during exercise, treatment may be adapted to energy demand. As a consequence, patients with exercise‐induced myopathy may be able to return to normal activity when provided with medium‐chain triglycerides (MCT) prior to exercise. There is no need to limit participation in sports. Progression of retinopathy in disorders of the mitochondrial trifunctional protein complex is closely associated with hydroxyacylcarnitine accumulation. A strict low‐fat diet with MCT supplementation is recommended to slow or prevent progression of chorioretinopathy. Additional docosahexanoic acid does not prevent the decline in retinal function but does promote nonspecific improvement in visual acuity and is recommended. There is no evidence that L‐carnitine supplementation is beneficial. Thus, supplementation with L‐carnitine in a newborn identified by screening with either a medium‐chain or long‐chain defect is not supported. With respect to the use of the odd‐chain medium‐chain triglyceride triheptanoin in myopathic phenotypes, randomized trials are needed to establish whether triheptanoin is more effective than even‐chain MCT. With increasing pathophysiological knowledge, new treatment options have been identified and are being clinically evaluated. These include the use of bezafibrates in myopathic long‐chain defects.Keywords
This publication has 39 references indexed in Scilit:
- Management and outcome in 75 individuals with long‐chain fatty acid oxidation defects: results from a workshopJournal of Inherited Metabolic Disease, 2009
- Treatment recommendations in long‐chain fatty acid oxidation defects: consensus from a workshopJournal of Inherited Metabolic Disease, 2009
- Carnitine palmitoyltransferase II deficiencyNeurology, 2008
- Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl–CoA dehydrogenase (MCAD)–deficient miceHepatology, 2008
- Ocular characteristics in 10 children with long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency: a cross‐sectional study with long‐term follow‐upActa Ophthalmologica, 2007
- Genetic Basis for Correction of Very-Long-Chain Acyl–Coenzyme A Dehydrogenase Deficiency by Bezafibrate in Patient Fibroblasts: Toward a Genotype-Based TherapyThe American Journal of Human Genetics, 2007
- Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencyMolecular Genetics and Metabolism, 2006
- Prolonged moderate‐intensity exercise without and with L‐carnitine supplementation in patients with MCAD deficiencyJournal of Inherited Metabolic Disease, 2006
- L‐Carnitine and exercise tolerance in medium‐chain acyl‐coenzyme A dehydrogenase (MCAD) deficiency: A pilot studyJournal of Inherited Metabolic Disease, 2004
- MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiencyThe Journal of Pediatrics, 2003